{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T03:28:48Z","timestamp":1786332528546,"version":"build-2736575974"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":66,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Castration-resistant prostate cancer (CRPC) is a fatal malignancy often associated with alterations in cell cycle regulation, particularly within the Cyclin\/CDK\/RB axis. Despite ongoing clinical trials assessing CDK4\/6 inhibitors in prostate cancer, clinical evidence remains limited. Although the androgen receptor (AR) inhibitor enzalutamide (ENZ) initially demonstrates therapeutic efficacy, resistance develops over time, and monotherapy offers limited antitumor benefits, highlighting the need for effective combination therapies. In this study, pharmacological profiling, genetic dependency analysis, RNA sequencing, and functional validation were conducted across various in vitro and in vivo preclinical CRPC models. The combination of ENZ and the CDK4\/6 inhibitor dalpiciclib (DAL) exhibited potent antitumor activity in CRPC cell lines, a cell-derived xenograft (CDX) model, and a lymphatic metastatic model. Moreover, ENZ plus DAL inhibited cell cycle progression, migration, and DNA replication, while promoting apoptosis in CRPC cells. Mechanistically, ENZ blocked AR-mediated transcriptional activation of MCM4, a critical component of the DNA helicase complex, thereby enhancing the effect of CDK4\/6 inhibition on DNA replication and inducing a pronounced synergistic antitumor response. These results suggest that the ENZ-DAL combination is a promising therapeutic approach that warrants further clinical evaluation in CRPC patients.<\/jats:p>","DOI":"10.1038\/s41419-026-08959-9","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T03:37:20Z","timestamp":1780630640000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The CDK4\/6 inhibitor dalpiciclib augments the antitumor efficacy of enzalutamide in preclinical models of castration-resistant prostate cancer through inhibition of MCM4-mediated DNA replication"],"prefix":"10.1038","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0203-5018","authenticated-orcid":false,"given":"Yue","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingtian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengting","family":"Chai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linhui","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunqian","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyu","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyuan","family":"Xiong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jialiang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenpeng","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3732-3868","authenticated-orcid":false,"given":"Chaoyan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6518-4013","authenticated-orcid":false,"given":"Haijun","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"8959_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73:17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"8959_CR2","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1038\/nrd4068","volume":"12","author":"D Trewartha","year":"2013","unstructured":"Trewartha D, Carter K. Advances in prostate cancer treatment. Nat Rev Drug Discov. 2013;12:823\u20134.","journal-title":"Nat Rev Drug Discov"},{"key":"8959_CR3","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.euf.2019.01.016","volume":"5","author":"A Davies","year":"2019","unstructured":"Davies A, Conteduca V, Zoubeidi A, Beltran H. Biological evolution of castration-resistant prostate cancer. Eur Urol Focus. 2019;5:147\u201354.","journal-title":"Eur Urol Focus"},{"key":"8959_CR4","doi-asserted-by":"publisher","first-page":"2583","DOI":"10.1002\/cncr.26582","volume":"118","author":"JA Garcia","year":"2012","unstructured":"Garcia JA, Rini BI. Castration-resistant prostate cancer: many treatments, many options, many challenges ahead. Cancer. 2012;118:2583\u201393.","journal-title":"Cancer"},{"key":"8959_CR5","doi-asserted-by":"publisher","first-page":"e004191","DOI":"10.1136\/jitc-2021-004191","volume":"10","author":"S Terrisse","year":"2022","unstructured":"Terrisse S, Goubet AG, Ueda K, Thomas AM, Quiniou V, Thelemaque C, et al. Immune system and intestinal microbiota determine efficacy of androgen deprivation therapy against prostate cancer. J Immunother Cancer. 2022;10:e004191.","journal-title":"J Immunother Cancer"},{"key":"8959_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1126\/science.1168175","volume":"324","author":"C Tran","year":"2009","unstructured":"Tran C, Ouk S, Clegg NJ, Chen Y, Watson PA, Arora V, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324:787\u201390.","journal-title":"Science"},{"key":"8959_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bph.15300","volume":"178","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen J, Wu Z, Ding W, Gao S, Gao Y, et al. Mechanisms of enzalutamide resistance in castration-resistant prostate cancer and therapeutic strategies to overcome it. Br J Pharm. 2021;178:239\u201361.","journal-title":"Br J Pharm"},{"key":"8959_CR8","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033667","volume":"10","author":"T Scheinberg","year":"2020","unstructured":"Scheinberg T, Kench J, Stockler M, Mahon KL, Sebastian L, Stricker P, et al. Pharmacodynamics effects of CDK4\/6 inhibitor LEE011 (ribociclib) in high-risk, localised prostate cancer: a study protocol for a randomised controlled phase II trial (LEEP study: LEE011 in high-risk, localised prostate cancer). BMJ Open. 2020;10:e033667.","journal-title":"BMJ Open"},{"key":"8959_CR9","doi-asserted-by":"publisher","first-page":"7783","DOI":"10.1158\/0008-5472.CAN-05-4472","volume":"66","author":"Y Xu","year":"2006","unstructured":"Xu Y, Chen SY, KN Ross, Balk SP. Androgens induce prostate cancer cell proliferation through mammalian target of rapamycin activation and post-transcriptional increases in Cyclin D proteins. Cancer Res. 2006;66:7783\u201392.","journal-title":"Cancer Res"},{"key":"8959_CR10","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S1470-2045(23)00172-9","volume":"24","author":"P Zhang","year":"2023","unstructured":"Zhang P, Zhang Q, Tong Z, Sun T, Li W, Ouyang Q, et al. Dalpiciclib plus letrozole or anastrozole versus placebo plus letrozole or anastrozole as first-line treatment in patients with hormone receptor-positive, HER2-negative advanced breast cancer (DAWNA-2): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2023;24:646\u201357.","journal-title":"Lancet Oncol"},{"key":"8959_CR11","doi-asserted-by":"publisher","first-page":"101243","DOI":"10.1016\/j.tranon.2021.101243","volume":"15","author":"G Guney Eskiler","year":"2022","unstructured":"Guney Eskiler G, Deveci Ozkan A, Haciefendi A, Bilir C. Mechanisms of abemaciclib, a CDK4\/6 inhibitor, induced apoptotic cell death in prostate cancer cells in vitro. Transl Oncol. 2022;15:101243.","journal-title":"Transl Oncol"},{"key":"8959_CR12","doi-asserted-by":"publisher","first-page":"7928937","DOI":"10.1155\/2021\/7928937","volume":"2021","author":"X Liu","year":"2021","unstructured":"Liu X, Liu Y, Wang Q, Song S, Feng L, Shi C. The alterations and potential roles of MCMs in breast cancer. J Oncol. 2021;2021:7928937.","journal-title":"J Oncol"},{"key":"8959_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-57299-1","volume":"14","author":"Y Li","year":"2024","unstructured":"Li Y, Gao W, Yang Z, Hu Z, Li J. Multi-omics pan-cancer analyses identify MCM4 as a promising prognostic and diagnostic biomarker. Sci Rep. 2024;14:6517.","journal-title":"Sci Rep"},{"key":"8959_CR14","doi-asserted-by":"publisher","DOI":"10.1186\/s13019-025-03481-z","volume":"20","author":"Y Cai","year":"2025","unstructured":"Cai Y, Lu X, Li T, Liu J, Jiang L. Transcription factor E2F1 promotes non-small cell lung cancer progression by activating the PI3K\/AKT pathway through MCM4. J Cardiothorac Surg. 2025;20:244.","journal-title":"J Cardiothorac Surg"},{"key":"8959_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2021.100996","volume":"297","author":"H Liu","year":"2021","unstructured":"Liu H, Lu Z, Shi X, Liu L, Zhang P, Golemis EA, et al. HSP90 inhibition downregulates DNA replication and repair genes via E2F1 repression. J Biol Chem. 2021;297:100996.","journal-title":"J Biol Chem"},{"key":"8959_CR16","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1004324","volume":"12","author":"S Yang","year":"2022","unstructured":"Yang S, Yuan Y, Ren W, Wang H, Zhao Z, Zhao H, et al. MCM4 is a novel prognostic biomarker and promotes cancer cell growth in glioma. Front Oncol. 2022;12:1004324.","journal-title":"Front Oncol"},{"key":"8959_CR17","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.3390\/diagnostics15121555","volume":"15","author":"HC Lai","year":"2025","unstructured":"Lai HC, Liu JF, Chang TM, Ling TY. MCM4 as potential metastatic biomarker in lung adenocarcinoma. Diagnostics. 2025;15:1555.","journal-title":"Diagnostics"},{"key":"8959_CR18","doi-asserted-by":"publisher","first-page":"3818","DOI":"10.3390\/ijms20153818","volume":"20","author":"P Ahluwalia","year":"2019","unstructured":"Ahluwalia P, Mondal AK, Bloomer C, Fulzele S, Jones K, Ananth S, et al. Identification and clinical validation of a novel 4 gene-signature with prognostic utility in colorectal cancer. Int J Mol Sci. 2019;20:3818.","journal-title":"Int J Mol Sci"},{"key":"8959_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1002\/tox.24433","volume":"40","author":"X Zhang","year":"2025","unstructured":"Zhang X, Dong M, Zheng G, Sun M, Zhang C, Zhou Z, et al. MCM4 promotes the progression of malignant melanoma by activating the PI3K\/AKT pathway. Environ Toxicol. 2025;40:306\u201317.","journal-title":"Environ Toxicol"},{"key":"8959_CR20","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1016\/j.eururo.2023.04.021","volume":"84","author":"O Bergengren","year":"2023","unstructured":"Bergengren O, Pekala KR, Matsoukas K, Fainberg J, Mungovan SF, Bratt O, et al. 2022 update on prostate cancer epidemiology and risk factors-a systematic review. Eur Urol. 2023;84:191\u2013206.","journal-title":"Eur Urol"},{"key":"8959_CR21","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1016\/j.ddstr.2011.02.004","volume":"7","author":"JB Aragon-Ching","year":"2010","unstructured":"Aragon-Ching JB, Dahut WL. Novel androgen deprivation therapy (ADT) in the treatment of advanced prostate cancer. Drug Discov Today Ther Strateg. 2010;7:31\u201335.","journal-title":"Drug Discov Today Ther Strateg"},{"key":"8959_CR22","doi-asserted-by":"publisher","first-page":"S110","DOI":"10.1038\/modpathol.2017.158","volume":"31","author":"AJ Evans","year":"2018","unstructured":"Evans AJ. Treatment effects in prostate cancer. Mod Pathol. 2018;31:S110\u2013S121.","journal-title":"Mod Pathol"},{"key":"8959_CR23","doi-asserted-by":"publisher","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","volume":"21","author":"EM Schaeffer","year":"2023","unstructured":"Schaeffer EM, Srinivas S, Adra N, An Y, Barocas D, Bitting R, et al. Prostate cancer, Version 4.2023, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw. 2023;21:1067\u201396.","journal-title":"J Natl Compr Cancer Netw"},{"key":"8959_CR24","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","volume":"70","author":"TC Chou","year":"2010","unstructured":"Chou TC. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010;70:440\u20136.","journal-title":"Cancer Res"},{"key":"8959_CR25","doi-asserted-by":"publisher","first-page":"D1670","DOI":"10.1093\/nar\/gkae973","volume":"53","author":"S Jiang","year":"2025","unstructured":"Jiang S, Li H, Zhang L, Mu W, Zhang Y, Chen T, et al. Generic Diagramming Platform (GDP): a comprehensive database of high-quality biomedical graphics. Nucleic Acids Res. 2025;53:D1670\u2013D1676.","journal-title":"Nucleic Acids Res"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08959-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08959-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T02:57:34Z","timestamp":1786330654000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-026-08959-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":25,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8959"],"URL":"https:\/\/doi.org\/10.1038\/s41419-026-08959-9","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"assertion":[{"value":"21 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All animal experiments were reviewed and approved by the Experimental Animal Welfare Ethics Committee of Zhongnan Hospital of Wuhan University (approval number: ZN2024217).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Ethics"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"703"}}